IA
FULC icon

IFP Advisors’s Fulcrum Therapeutics FULC Stock Holding History

IFP Advisors’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.01K Buy
1,368
+380
+38% +$2.31K ﹤0.01% 3791
2026
Q1 		$7.58K Hold
988
– – ﹤0.01% 3300
2025
Q4 		$11.2K Sell
988
-988
-50% -$10.1K ﹤0.01% 3001
2025
Q3 		$18.2K Buy
1,976
+368
+23% +$2.66K ﹤0.01% 2624
2025
Q2 		$16.1K Sell
1,608
-1,204
-43% -$6.44K ﹤0.01% 2655
2025
Q1 		$8.1K Buy
2,812
+518
+23% +$1.9K ﹤0.01% 2652
2024
Q4 		$11K Buy
2,294
+1,393
+155% +$5.14K ﹤0.01% 2492
2024
Q3 		$3.21K Buy
+901
New +$6.68K ﹤0.01% 2797

Other funds holding FULC

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

IFP Advisors's FULC Position: Q2 2026 in Review

IFP Advisors increased its Fulcrum Therapeutics (FULC) stake by 38% in Q2 2026, buying an estimated $2.31K and bringing the position to 1,368 shares worth $5.01K. The position accounts for ﹤0.01% of the portfolio, ranked #3791.

IFP Advisors first reported a position in FULC in Q3 2024 and has held it in 8 quarters since. The position peaked at $18.2K in Q3 2025. 155 funds tracked by Wall St. Rank hold FULC as of Q2 2026.

  • IFP Advisors held 1,368 shares of Fulcrum Therapeutics worth $5.01K as of Q2 2026.
  • IFP Advisors bought 380 Fulcrum Therapeutics shares in Q2 2026, an estimated $2.31K.
  • Fulcrum Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #3791 holding.
  • IFP Advisors first reported a position in Fulcrum Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • IFP Advisors's Fulcrum Therapeutics position peaked at $18.2K in Q3 2025.
  • 155 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.